Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This study will evaluate the efficacy, safety and tolerability of Torvutatug samrotecan (torvu-sam) in combination with bevacizumab compared with bevacizumab monotherapy as first line maintenance treatment in patients with Homologous Recombination Deficient (HRD) negative advanced ovarian cancer.
Epistemonikos ID: 2c4fa4bbff047a286d85627b53998494da6015d0
First added on: Oct 02, 2026